Alcoholic hepatitis is referred as an acute but destructive form of liver disease that is characterized by increased bilirubin level. The normal bilirubin level for a healthy adult is 1.2 mg/dl whereas the bilirubin level in alcoholic hepatitis is over 10-15 mg/dl. The symptoms for the disease include loss of appetite, nausea, abnormal tenderness, low grade fever, fatigue, weakness, malnutrition, fluid accumulation in abdomen part, behavioral changes, confusion, and kidney and liver failure. The cause of alcoholic hepatitis is higher intake of alcohol. Some of the extensively used drugs for treatment of alcoholic hepatitis therapeutics include pentoxifylline, nutritional therapy, anabolic steroids and other hemorheological agents. The alcoholic hepatitis has the following symptoms like belly tenderness or pain over the liver, nausea, vomiting blood, poor appetite, yellowing of the skin and eyes, weight loss, tiredness and weakness, fever. The goal of the treatment follows the restoration of some or all functioning of the liver. There is no proper treatment medicine to cure alcoholic hepatitis. The available treatment only involves easing the symptoms and keeping the disease from getting worse.
COVID-19 scenario analysis:
Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine, have witnessed surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunity for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.
Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis
Increase in popularity of the alcoholic hepatitis disease like cirrhosis, fatty liver, etc. are helping in the growth of the alcoholic hepatitis therapeutics market. The developments in the technology and science behind it has increased the knowledge about the treatment for the disease, which also leads to the growth of the market.
Alcoholic hepatitis therapeutics manufacturers and research laboratories are collaborating together and this is anticipated to offer significant growth opportunities in the market.
Governments are also backing and various strategies and activities are being performed to diminish ecological contamination and rise in sanitation concerns and the developing oil industry.
The alcoholic hepatitis therapeutics market restrains are increase in the health care expenditure, forceful reimbursement of the policies and greater development cost.
New product launches to flourish the market:
R&D activities have revealed that modification of gut microbiota and products related to it, including nutritional intervention, increasing steroid sensitivity, lipopolysaccharide, immune modulation, and epigenetic modification of liver damage caused by alcohol, are some of the ground breaking avenues in the alcoholic hepatitis therapeutics market that are expected to offer tremendous promise during the forecast period.
In July 2004, Merck Sante s.a.s., the subsidiary of Merck KgaA received an approval for Campral by the FDA. This drug has the potential to treat heavy alcoholism.
In 2006, Endo Laboratories received permission for Vivitrol injection by the FDA. This drug is active against alcohol dependence.
Surge in usage in hospital applications:
Increasing incidence of liver diseases and high success rate of alcoholic hepatitis drugs are some factors that are expected to hike the demand of the global alcoholic hepatitis therapeutics market. Furthermore, increase in awareness about the developments in drugs technology will help the drug usage to surge in the hospital sectors.
Key benefits of the report:
- This study presents the analytical depiction of the global alcoholic hepatitis therapeutics industry along with the current trends and future estimations to determine the imminent investment pockets.
- The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global alcoholic hepatitis therapeutics market share.
- The current market is quantitatively analyzed to highlight the global market growth scenario.
- Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
- The report provides a detailed global alcoholic hepatitis therapeutics market analysis based on competitive intensity and how the competition will take shape in coming years.
Questions answered in the alcoholic hepatitis therapeutics market research report:
- What are the leading market players active in the alcoholic hepatitis therapeutics market?
- What the current trends will influence the market in the next few years?
- What are the driving factors, restraints, and opportunities in the market?
- What are the projections for the future that would help in taking further strategic steps?
Alcoholic Hepatitis Therapeutics Market Report Highlights
| Aspects | Details |
 By Drug Type |
|
 By Application |
|
 By DISTRIBUTION CHANNEL |
|
 By Region |
|
 Key Market Players | Dainippon sumitomo pharma Co. ltd., Immuron limited, Intercept Pharmaceuticals Inc., Conatus pharmaceuticals Inc., Siesta Pharmaceuticals, Generon corporation Ltd., Teva Pharmaceuticals Ltd., Lupin Laboratories Ltd., Alfact Innovation, Alkermes Inc., Sanofi-Aventis, others. |
Loading Table Of Content...
